Executives from 4D Molecular Therapeutics (NASDAQ:FDMT) provided updates on the company’s late-stage ophthalmology program, commercialization planning, cystic fibrosis development efforts, and cash ...
Following a second injection at eight weeks, the patient maintained stable vision and remained dry at 12 weeks, allowing for ...
Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to date Initiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) ...
Today, the durable medical equipment management (DME) process can be fragmented, inefficient, and unreliable - leading to errors and delays that impact member health, inflate costs for health plans, ...
Eyepoint Pharmaceuticals (NASDAQ:EYPT) outlined late-stage clinical progress for its lead retinal candidate DURAVYU and ...
EMERYVILLE, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...
Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 –– Patients dosed in both COMO and ...
– Phase 3 LUGANO and LUCIA clinical trials for DURAVYU ™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 – – Announced initiation of pivotal Phase 3 DME program ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results